In summary, differences in expression patterns of proteins involved in PI3K, mTOR, and MAPK pathways, as well as kinase activity markers, ultimately explain why AML cell lines respond to the cotreatment in a distinct manner. Here, PIK3CA is linked to acute myeloid leukemia.